Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors

被引：39
|
作者：
Sequist, Lecia V. [1 ]
Cassier, Phillippe [2 ]
Varga, Andrea [3 ]
Tabernero, Josep [4 ]
Schellens, Jan H. [5 ]
Delord, Jean-Pierre [6 ]
LoRusso, Patricia [7 ]
Camidge, D. Ross [8 ]
Hidalgo Medina, Manuel [9 ]
Schuler, Martin [10 ]
Campone, Mario [11 ]
Tian, G. Gary [12 ]
Wong, Steven [13 ]
Corral, Jesus [14 ]
Isaacs, Randi [15 ]
Sen, Suman K. [16 ]
Porta, Diana Graus [17 ]
Kulkarni, Swarupa G. [16 ]
Lefebvre, Caroline [18 ]
Wolf, Juergen [19 ]
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Ctr Leon Berard, F-69373 Lyon, France
[3] Inst Gustave Roussy, Villejuif, France
[4] Vall dHebron Univ Hosp, Barcelona, Spain
[5] Netherlands Canc Inst, Amsterdam, Netherlands
[6] Inst Claudius Regaud, Toulouse, France
[7] Karmanos Canc Inst, Detroit, MI USA
[8] Univ Colorado, Aurora, CO USA
[9] Spanish Natl Canc Res Ctr CNIO, Madrid, Spain
[10] Univ Duisburg Essen, West German Canc Ctr, Essen, Germany
[11] Ctr Rene Gauducheau, F-44035 Nantes, France
[12] West Clin, Memphis, TN USA
[13] UCLA Med Ctr, Los Angeles, CA USA
[14] Univ Hosp Virgen del Rocio, Seville, Spain
[15] Novartis OTM, E Hanover, NJ USA
[16] Novartis Pharmaceut, E Hanover, NJ USA
[17] NIBR Oncol, Basel, Switzerland
[18] Novartis OTM, Basel, Switzerland
[19] Univ Hosp Cologne, Cologne, Germany
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-CT326
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT326
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A phase Ib study of BGJ398 in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST).
    Kelly, Clara Marie
    Shoushtari, Alexander Noor
    Qin, Li-Xuan
    D'Arigelo, Sandra P.
    Dickson, Mark Andrew
    Gounder, Mrinal M.
    Keohan, Mary Louise
    Sjoberg, Ana
    Mcfaclyen, Chloe
    Hwang, Sinchun
    Heinemann, M. H.
    Francis, Jasmine
    Singer, Samuel
    DeMatteo, Ronald P.
    Antonescu, Cristina R.
    Chi, Ping
    Tap, William D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] A phase 1, dose-escalation, first-in-human study of ARQ 087, an oral pan-FGFR inhibitor, in adult subjects with advanced solid tumors
    Papadopoulos, K.
    Tolcher, A.
    Kittaneh, M.
    Patniak, A.
    Rasco, D.
    Chambers, G.
    Newth, G.
    Savage, R.
    Hall, T.
    Schwartz, B.
    Kazakin, J.
    LoRusso, P.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 125 - 125
  • [23] INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
    Lassman, A. B.
    Sepulveda-Sanchez, J. M.
    Cloughesy, T.
    Gil-Gil, J. M.
    Puduvalli, V. K.
    Raizer, J.
    De Vos, F. Y.
    Wen, P. Y.
    Butowski, N.
    Clement, P.
    Groves, M. D.
    Belda-Iniesta, C.
    Steward, K.
    Moran, S.
    Ye, Y.
    Roth, P.
    NEURO-ONCOLOGY, 2019, 21 : 21 - 22
  • [24] INFIGRATINIB (BGJ398) IN PATIENTS WITH RECURRENT GLIOMAS WITH FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) ALTERATIONS: A MULTICENTER PHASE II STUDY
    Lassman, Andrew
    Sepulveda-Sanchez, Juan
    Cloughesy, Timothy
    Gil-Gil, Juan
    Puduvalli, Vinay
    Raizer, Jeffrey
    De Vos, Filip
    Wen, Patrick
    Butowski, Nicholas
    Clement, Paul
    Groves, Morris
    Belda-Iniesta, Cristobal
    Steward, Keith
    Rowsey, Steven
    Ye, Yining
    Roth, Patrick
    NEURO-ONCOLOGY, 2019, 21 : 20 - 20
  • [25] Infigratinib (BGJ 398), a Pan-FGFR Inhibitor, Targets P-Glycoprotein and Increases Chemotherapeutic-Induced Mortality of Multidrug-Resistant Tumor Cells
    Boichuk, Sergei
    Dunaev, Pavel
    Mustafin, Ilshat
    Mani, Shinjit
    Syuzov, Kirill
    Valeeva, Elena
    Bikinieva, Firuza
    Galembikova, Aigul
    BIOMEDICINES, 2022, 10 (03)
  • [26] Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors
    Xu, J.
    Wang, Y.
    Ye, C. Y.
    Huang, C.
    Zhang, X. H.
    Sai, Y.
    Shen, L.
    Mu, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Selective FGFR inhibitor BGJ398 inhibits phosphorylation of AKT and STAT3 and induces cytotoxicity in sphere-cultured ovarian cancer cells
    Cha, Hwa Jun
    Choi, Jung Hye
    Parks, In Chul
    Kim, Chun Ho
    An, Sung Kwan
    Kim, Tae Jin
    Lee, Jae Ho
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 50 (04) : 1279 - 1288
  • [28] Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis
    Zheng, Xinyi
    Wang, Hang
    Deng, Junyue
    Yao, Minghe
    Zou, Xiuhe
    Zhang, Fan
    Ma, Xuelei
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [29] Phase I study evaluating KIN-3248, a next-generation, irreversible pan-FGFR inhibitor, in patients with advanced cholangiocarcinoma, urothelial carcinoma and other solid tumors harboring FGFR2 and/or FGFR3 gene alterations
    Garmezy, B.
    Borad, M.
    Lin, C. C.
    Chen, L. T.
    Perez, C. A.
    Kato, S.
    Tam, B.
    Severson, P.
    Quah, C. S.
    Harding, J. J.
    ANNALS OF ONCOLOGY, 2023, 34 : S231 - S232
  • [30] Marker lesion study of oral FGFR inhibitor BGJ398 in patients with FGFR3-altered intermediate-risk nonmuscle-invasive bladder cancer
    Cha, Eugene K.
    Iyer, Gopa
    Funt, Samuel Aaron
    Regazzi, Ashley Marie
    Francis, Jasmine
    Heinemann, M. H.
    Ostrovnaya, Irina
    Dalbagni, Guido
    Bajorin, Dean F.
    Bochner, Bernard H.
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345